556 related articles for article (PubMed ID: 26172084)
61. Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine (300 Units per Milliliter) in a Real-World Setting: A Retrospective Observational Study.
Gupta S; Wang H; Skolnik N; Tong L; Liebert RM; Lee LK; Stella P; Cali A; Preblick R
Adv Ther; 2018 Jan; 35(1):43-55. PubMed ID: 29313285
[TBL] [Abstract][Full Text] [Related]
62. Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
Battelino T; Danne T; Edelman SV; Choudhary P; Renard E; Westerbacka J; Mukherjee B; Pilorget V; Coudert M; Bergenstal RM
Diabetes Obes Metab; 2023 Feb; 25(2):545-555. PubMed ID: 36263928
[TBL] [Abstract][Full Text] [Related]
63. Glycaemic goal attainment and hypoglycaemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naïve cohort study.
Bailey TS; Zhou FL; Gupta RA; Preblick R; Gupta VE; Berhanu P; Blonde L
Diabetes Obes Metab; 2019 Jul; 21(7):1596-1605. PubMed ID: 30843339
[TBL] [Abstract][Full Text] [Related]
64. Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial.
Philis-Tsimikas A; Klonoff DC; Khunti K; Bajaj HS; Leiter LA; Hansen MV; Troelsen LN; Ladelund S; Heller S; Pieber TR;
Diabetologia; 2020 Apr; 63(4):698-710. PubMed ID: 31984443
[TBL] [Abstract][Full Text] [Related]
65. Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trial.
Meneghini L; Blonde L; Gill J; Dauchy A; Bacevicius A; Strong J; Bailey TS
Diabetes Obes Metab; 2020 Nov; 22(11):1995-2003. PubMed ID: 32538550
[TBL] [Abstract][Full Text] [Related]
66. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
67. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
68. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
Polonsky W; Traylor L; Gao L; Wei W; Ameer B; Stuhr A; Vlajnic A
J Diabetes Complications; 2017 Mar; 31(3):562-568. PubMed ID: 28040350
[TBL] [Abstract][Full Text] [Related]
69. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
70. A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study.
Meneghini LF; Sullivan SD; Oster G; Busch R; Cali AMG; Dauchy A; Gill J; Bailey TS
Diabetes Obes Metab; 2020 Nov; 22(11):2004-2012. PubMed ID: 32729217
[TBL] [Abstract][Full Text] [Related]
71. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
72. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
73. Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme.
Blonde L; Bailey T; Sullivan SD; Freemantle N
Diabetes Obes Metab; 2021 Aug; 23(8):1713-1721. PubMed ID: 33881797
[TBL] [Abstract][Full Text] [Related]
74. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial.
Rodbard HW; Cariou B; Zinman B; Handelsman Y; Philis-Tsimikas A; Skjøth TV; Rana A; Mathieu C;
Diabet Med; 2013 Nov; 30(11):1298-304. PubMed ID: 23952326
[TBL] [Abstract][Full Text] [Related]
75. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting.
Pfohl M; Jornayvaz FR; Fritsche A; Pscherer S; Anderten H; Pegelow K; Seufert J
Diabetes Obes Metab; 2020 May; 22(5):759-766. PubMed ID: 31903680
[TBL] [Abstract][Full Text] [Related]
76. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
77. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
Karl DM; Gill J; Zhou R; Riddle MC
Diabetes Obes Metab; 2013 Jul; 15(7):622-8. PubMed ID: 23350795
[TBL] [Abstract][Full Text] [Related]
78. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
[TBL] [Abstract][Full Text] [Related]
79. Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.
Freemantle N; Chou E; Frois C; Zhuo D; Lehmacher W; Vlajnic A; Wang H; Chung HW; Zhang Q; Wu E; Gerrits C
BMJ Open; 2016 Feb; 6(2):e009421. PubMed ID: 26880669
[TBL] [Abstract][Full Text] [Related]
80. Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics.
Ritzel R; Ghosh S; Emral R; Malek R; Zeng L; Mabunay MA; Landgraf W; Guyot P; Serafini P; Pushkarna D; Malik RA
Diabetes Obes Metab; 2023 Sep; 25(9):2495-2504. PubMed ID: 37312665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
